Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 171Lymphoma 93Leukemia 63Burkitt Lymphoma 57Lymphoma, Non-Hodgkin 50Lymphoma, Large B-Cell, Diffuse 44Lymphoma, Mantle-Cell 38Lymphoma, Follicular 30Recurrence 29Hodgkin Disease 29Waldenstrom Macroglobulinemia 27Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Leukemia, Lymphocytic, Chronic, B-Cell 26Multiple Myeloma 21Lymphoma, B-Cell, Marginal Zone 17Lymphoma, Extranodal NK-T-Cell 16Leukemia, Biphenotypic, Acute 16Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, B-Cell 13Leukemia, Myeloid, Acute 13Lymphoma, Large-Cell, Immunoblastic 11Lymphoma, T-Cell, Peripheral 10Neoplasms 9Lymphoma, Large-Cell, Anaplastic 9Lymphoma, T-Cell, Cutaneous 8Lymphoma, T-Cell 7Intraocular Lymphoma 6Hematologic Neoplasms 6Blast Crisis 6Sezary Syndrome 5

Interventions

midostaurin 3avapritinib 2ripretinib 1nilotinib 1ibrutinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Ranitidine 1Interviews as Topic 1Ibuprofen 1Diphenhydramine 1Dexamethasone 1Calcium Dobesilate 1Brentuximab Vedotin 1Azacitidine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Dexamethasone × Lymphoid × Clear all
NCT04681105 2026-01-28

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

City of Hope Medical Center

Phase 1 Completed
13 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Mastocytosis, Systemic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡